Affiliation:
1. Wuhan No.1 Hospital
2. Tongji Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology
3. Fudan University
Abstract
Abstract
Purpose
BCL9 contributed to tumor progression and metastasis in various tumors, whereas, the role of BCL9 in papillary thyroid cancer (PTC) hasn’t been investigated.
Methods
We acquired PTC gene expression data from The Cancer Genome Atlas (TCGA) databases. 59 PTC tissues were applied to validate the clinical significance of BCL9. Cell experiments were applied to investigate the role of BCL9. Bioinformatics analysis were employed to investigate the biological functions of BCL9.
Results
We found that BCL9 was higher expressed (P ༜ 0.05) and an independent risk factor for lymph node metastasis (OR = 3.770, P = 0.025), as well as associated with poorer progression free survival (PFS) (P = 0.049) in PTC. BCL9 knockdown inhibited proliferation and invasion of PTC cells. BCL9 was positively associated with the key genes of Wnt/β-catenin and MAPK pathway by Co-expression analysis. GO, KEGG and GSEA analysis showed BCL9 might participated in PPAR, cAMP, and focal adhesion pathway. CIBERSORT analysis found BCL9 was negatively associated with CD8 + T cells and NK cells infiltration and positively with PD-L1 expression.
Conclusion
Therefore, BCL9 was associated with lymph node metastasis and shorter PFS of PTC, due to promotion of PTC cell proliferation and invasion, activation of Wnt/β-catenin and MAPK pathway, inhibition of CD8 + T and NK cells infiltration, and promotion of PD-L1 expression.
Publisher
Research Square Platform LLC